Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress

Proactive Investors video interview with Amplia Therapeutics Limited (ASX:ATX) CEO Dr Chris Burns with promising updates from the ongoing Phase 2a clinical trial for the treatment of advanced Pancreatic cancer